Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Gilead Sciences Completes Acquisition of Arcellx and Anito-cel

AI-generated analysis

πŸ“ˆ Gilead Sciences completed its acquisition of Arcellx, Inc. on April 28, 2026, for approximately $7.8 billion in equity value.

πŸ’Š The deal grants Gilead full control of anito-cel, a BCMA-directed CAR T-cell therapy for multiple myeloma with FDA expedited designations.

πŸ’° Investors received $115 per Arcellx share plus a $5 non-transferable contingent value right (CVR) in the transaction.

πŸ“‰ The acquisition is structured as an asset purchase expected to reduce Gilead's 2026 EPS by approximately $5.57–$5.67 due to cash payments and dilution.

πŸ’Ή Profit from the deal will not be recognized until 2028, contingent on achieving at least $6 billion in cumulative global net sales for anito-cel by end-2029.

🏒 Arcellx will become a wholly owned subsidiary of Gilead and is set to be delisted from Nasdaq following the merger.

πŸ“Š Analysts currently rate Gilead (GILD) as a Buy with a price target of $160.00 based on strong financial performance and technical momentum.

πŸš€ Gilead plans a major $32 billion capital commitment in the United States to expand manufacturing capacity, drug discovery, and job creation announced in 2025.

🌍 The company operates as a global biopharmaceutical leader focusing on HIV, viral hepatitis, cancer, and inflammation across more than 35 countries.

Bullish Signals
  • Gilead Sciences successfully completed the acquisition of Arcellx, Inc., gaining full control of anito-cel and removing future profit-sharing obligations tied to the program.
  • The company paid $115 in cash per Arcellx share plus a $5 non-transferable contingent value right, implying equity value of about $7.8 billion for the transaction.
  • Approximately 77.2% of Arcellx shares were tendered in the offer that closed on April 28, 2026, with Arcellx now a wholly owned subsidiary to be delisted from Nasdaq.
  • Anito-cel is an investigational BCMA-directed CAR T-cell therapy for multiple myeloma holding multiple expedited U.S. FDA designations, indicating strong regulatory potential.
  • The transaction is expected to become accretive starting in 2028, contingent on the commercial success of anito-cel and achieving at least $6.0 billion in cumulative global net sales by end-2029.
  • Analysts maintain a Buy rating with a price target of $160.00 for Gild stock (GILD), while TipRanks' AI Analyst rates it as an Outperform based on strong financial performance and constructive technical momentum.
  • Gilead plans a major $32 billion investment in the United States announced in 2025 to expand its domestic footprint, supporting drug discovery, manufacturing capacity, and job creation.
Risk Factors
  • The acquisition of Arcellx reduces Gilead's 2026 GAAP and non-GAAP diluted EPS by around $5.57–$5.67, creating immediate financial headwinds.
  • The transaction is modestly dilutive in 2026 and 2027 before becoming accretive from 2028 onward, introducing uncertainty dependent on future regulatory approvals and commercial success.
  • The contingent value rights require anito-cel to achieve at least $6.0 billion in cumulative global net sales by end-2029, setting a high bar for future profitability obligations.
  • Valuation is not clearly cheap at ~22.5x earnings with only a ~2.1% dividend yield, leaving limited margin of safety given policy and cell-therapy headwinds.
  • Gilead faces potential policy and cell-therapy headwinds that temper upside despite strong financial performance in HIV and cancer segments.
Full Analysis
On April 28, 2026, Gilead Sciences, Inc. finalized its acquisition of Arcellx, Inc., securing full control over anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for multiple myeloma. The therapeutic utilizes a novel D-Domain binder and currently holds multiple expedited U.S. FDA designations. Prior to the acquisition, the collaboration involved profit-sharing, milestone, and royalty obligations; following the deal, Gilead will manage these rights entirely through its Kite Oncology unit, which specializes in oncology portfolio development spanning antibody-drug conjugates, small molecules, and cell therapies. The transaction is structured as an asset acquisition and involves a tender offer that concluded with approximately 77.2% of shares tendered, followed by a merger that makes Arcellx a wholly owned subsidiary to be delisted from Nasdaq. The financial terms of the deal consist of $115 in cash per Arcellx share plus a $5 non-transferable contingent value right, implying an aggregate equity value of about $7.8 billion for the acquisition. The contingent value rights are specifically tied to achieving at least $6.0 billion in cumulative global net sales by the end of 2029. The transaction is expected to reduce Gilead’s 2026 GAAP and non-GAAP diluted earnings per share by an estimated range of $5.57 to $5.67, representing a modest dilution during 2026 and 2027, with accretiveness projected to begin from 2028 onward, contingent upon regulatory approval and the commercial success of anito-cel. Gilead Sciences operates as a global biopharmaceutical company headquartered in Foster City, California, focusing on developing innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, cancer, and inflammation across more than 35 countries. The company has outlined significant capital commitments in the United States, including a planned $32 billion investment announced in 2025 to expand its domestic footprint, support drug discovery, manufacturing capacity, job creation, and public health preparedness while continuing to fund global expansion for patient access. Analyst ratings on Gilead Sciences stock currently reflect a Buy rating with a $160.00 price target, driven primarily by strong financial performance including a rebound in profitability and consistently high free cash flow, alongside constructive technical momentum despite policy and cell-therapy headwinds.